Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Zealand Pharma A/S - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
ZLDPY
Over the counter
2830
www.zealandpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Zealand Pharma A/S
Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)
- Jun 29th, 2026 9:00 am
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
- Jun 22nd, 2026 2:00 pm
Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)
- Jun 22nd, 2026 9:00 am
[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
- Jun 16th, 2026 4:30 pm
Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)
- Jun 15th, 2026 9:00 am
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.
- Jun 8th, 2026 10:34 am
Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)
- Jun 8th, 2026 9:05 am
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
- Jun 8th, 2026 9:00 am
Why The Narrative Around Zealand Pharma (CPSE:ZEAL) Is Shifting After Target Resets And Trial Updates
- Jun 8th, 2026 12:11 am
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis
- Jun 7th, 2026 12:30 pm
New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity
- Jun 5th, 2026 2:45 pm
Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference
- Jun 2nd, 2026 9:00 am
Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)
- Jun 1st, 2026 9:00 am
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
- May 27th, 2026 9:00 am
Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions
- May 27th, 2026 1:00 am
Zealand Pharma - Transactions related to share buy-back program (week 21, 2026)
- May 26th, 2026 9:30 am
Resolutions from Zealand Pharma's Extraordinary General Meeting 2026
- May 26th, 2026 8:00 am
Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)
- May 14th, 2026 9:00 am
Is Zealand Pharma AS (ZLDPF) Stock Undervalued Right Now?
- May 12th, 2026 7:40 am
Zealand Pharma Obesity Trials Shape Future Revenue Potential And Partner Dependence
- May 11th, 2026 8:07 pm
Scroll